Policy Areas

Materials

  • Blog
  • News
10.08.2020
blog
During a challenging year, M&A activity in pharmaceutical markets was lower than experts estimated. Also, there were not many megadeals in Q1 and Q2 compared with 2019 (where the value of the largest deal was $99.5 billion). The biggest deals in the first half of 2020 were Thermo Fisher Scientific / Qiagen ($11.5 billion, COVID-19), Gilead Sciences / Forty Seven ($4.9 billion, oncology), Gilead Sciences / Pionyr Immunotherapeutics ($1.7 billion, oncology), Novo Nordisk / Corvidia ($2.1 billion, cardiometabolic diseases), Eli Lilly / Dermira ($1.1 billion, immunology, dermatology).
Expert at the BRICS Competition Centre
16.06.2020
news
The Federal Antimonopoly Service (FAS) has not agreed on the purchase by Yandex of the ‘Vezet’ taxi aggregator, as the deal would have led companies to dominate the taxi market in more than half of the Russian regions.
25.06.2015
news
On the 22-23rd June the BRICS Competition Law and Policy Forum took place at HSE St Petersburg. The international conference was organised jointly by the HSE-Skolkovo Institute for Law and Development, the Centre for Law, Economics and Society at UCL and the Russian Federal Antimonopoly Service (FAS). Heads of antitrust departments and experts from the BRICS and the EEC were joined by leading academics and experts on competition law from Europe and the US.